Refine
Year of publication
Document Type
- Article (55)
- Conference Proceeding (1)
Language
- English (56)
Has Fulltext
- yes (56)
Is part of the Bibliography
- no (56)
Keywords
- glioblastoma (17)
- hypoxia (7)
- glioma (6)
- Glioblastoma (4)
- Glioma (3)
- anti-angiogenic therapy (3)
- bevacizumab (3)
- brain metastases (3)
- temozolomide (3)
- EGFR (2)
- Fasting (2)
- Glucose (2)
- HOD (2)
- IDH mutation (2)
- Ketogenic diet (2)
- Leptin (2)
- MRI (2)
- PD-L1 (2)
- Radiation (2)
- Targeted therapy (2)
- Temozolomide (2)
- mTOR (2)
- metabolism (2)
- mitochondria (2)
- starvation (2)
- tumor microenvironment (2)
- 19F MR spectroscopy (1)
- 1H MR spectroscopy (1)
- 2-deoxyglucose (2-DG) (1)
- 2-hydroxyglutarate (1)
- ASA404 (1)
- ATP (1)
- Acute (1)
- Addison’s disease (1)
- Apoptosis (1)
- Astrocytoma (1)
- Ataxia (1)
- BRAF (1)
- BRAF V600E (1)
- Bevacizumab (1)
- Biomarker (1)
- Brain metastasis (1)
- Brain tumor (1)
- CD74 (1)
- CDK4/CDK6 (1)
- CMS (1)
- CNS tumor (1)
- Cancer (1)
- Cell Metabolism (1)
- Cell biology (1)
- Cerebellum (1)
- Clinical management (1)
- Concurrent CNS diseases (1)
- DDIT4 (1)
- DMXAA (1)
- DNA methylation (1)
- Dexamethasone (1)
- EGFRvIII mutation (1)
- Edema (1)
- Epidermal growth factor receptor (1)
- Grading (1)
- HLA class II (1)
- HLA peptidome (1)
- Hemosiderin (1)
- Holmes tremor (1)
- Hypoxia (1)
- IDH1 inhibitor (1)
- Isocitrate dehydrogenase (1)
- LC3B (1)
- Low grade glioma (1)
- MGMT (1)
- MGMT promoter (1)
- MR-spectroscopy (1)
- MRI patterns of gliomas (1)
- Mammalian target of rapamycin (1)
- Molecular matched therapy (1)
- Molecular profiling (1)
- Multiple sclerosis (1)
- NK-92 (1)
- NSCLC (1)
- Nimotuzumab (1)
- Obesity (1)
- Oligodendroglioma (1)
- PCV (1)
- PD-1 (1)
- PML (1)
- PWI (1)
- PXA (1)
- Pentose Pathway (1)
- Pseudoprogression (1)
- Radiation necrosis (1)
- STING (1)
- Side effect (1)
- Siderosis (1)
- TGF-β (1)
- TIGAR (1)
- TP53-induced glycolysis and apoptosis regulator (1)
- Tet-inducible system (1)
- Treatment outcome (1)
- Tumor infiltrating lymphocytes (1)
- Warburg effect (1)
- [18F]FET PET (1)
- adoptive cancer immunotherapy (1)
- adrenal insuffciency (1)
- apoptosis (1)
- astrocytoma (1)
- autophagy (1)
- biomarker (1)
- biomarkers (1)
- brain metastasis (1)
- brain tumor (1)
- cerebellar mutism (1)
- cerebellum (1)
- cerebral pseudoprogression (1)
- cerebral radiation necrosis (1)
- cetuximab-bevacizumab therapy sequence (1)
- chemotherapy (1)
- chimeric antigen receptor (1)
- clinical practice (1)
- colon carcinoma (1)
- dabrafenib (1)
- diet (1)
- diffuse low-grade glioma (1)
- doxycycline (1)
- epidermal growth factor receptor (1)
- fasting (1)
- galunisertib monohydrate (LY2157299) (1)
- gliomatosis cerebri growth pattern (1)
- glycolysis (1)
- hydrocephalus (1)
- hypoxia-induced cell death (1)
- hypoxia-inducible factor (1)
- image-guided tissue acquisition (1)
- immune checkpoint inhibitors (1)
- immune checkpoint inhibitors (ICI) (1)
- immune related adverse events (irAE) (1)
- immune response (1)
- immunotherapy (1)
- inducible gene expression (1)
- infiltration (1)
- intraventricular chemotherapy (1)
- invasive growth (1)
- irradiation (1)
- isocaloric ketogenic diet (1)
- ketogenic (1)
- ketone body (1)
- leptomeningeal disease (1)
- leptomeningeal metastases (1)
- mTOR inhibition (1)
- macrophage polarization (1)
- malignant glioma (1)
- medulloblastoma (1)
- medulloblastoma resection (1)
- meningioma (1)
- metabolic cancer therapy (1)
- miRNA (1)
- multifocal (1)
- murine model (1)
- natural killer cells (1)
- neoadjuvant immunochemotherapy (1)
- neuroimaging (1)
- neurological complication (1)
- neurological side effects (1)
- neurosurgery (1)
- nivolumab (1)
- p53 (1)
- pSMAD2 (1)
- palatal tremor (1)
- patterns of progression (1)
- pembrolizumab (1)
- pentose phosphate pathway (1)
- perioperative ischemia (1)
- pleomorphic xanthoastrocytoma (1)
- posterior fossa masses (1)
- primary brain tumors (1)
- quantitative MRI (1)
- radiation (1)
- reactive oxygen species (1)
- regorafenib (1)
- regorafenib csf concentration (1)
- signature (1)
- small molecule inhibitor (1)
- stereotactic radiosurgery (1)
- targeted therapy (1)
- tetracycline (1)
- therapy resistance (1)
- transketolase-like protein 1 (1)
- tumor angiogenesis (1)
- tumor metabolism (1)
- tumor-infiltrating lymphocytes (1)
- vadimezan (1)
- vascular disrupting agents (1)
- vascular endothelial growth factor receptor (1)
- ventriculoperitoneal shunt (1)
Institute
Introduction: The concurrent presence of both central nervous system (CNS) tumors and multiple sclerosis (MS) poses various diagnostic and therapeutic pitfalls and makes the clinical management of such patients challenging.
Methods: In this retrospective, single-center cohort study, we searched our clinical databases (2006–2019) for patients with concurrent CNS tumors and MS and described their disease courses. Age at diagnosis of the respective disease and probabilities for MS disease activity events (DAEs) with vs. without prior tumor-specific therapy were tested pairwise using t-test for dependent samples and exact binomial test.
Results: N = 16 patients with concurrent CNS tumors and MS were identified. MS diagnosis preceded the CNS oncological diagnosis by an average of 9 years (p = 0.004). More DAEs occurred in patients without prior chemotherapy (83.3%) than in patients with prior chemotherapy (16.7%; p = 0.008). This effect did not reach significance for patients with prior radiation therapy/radiosurgery (66.7% vs. 33.3%, p = 0.238). The average interval between DAEs and the last documented lymphopenia was 32.25 weeks.
Conclusions: This study describes the clinical and demographic features of patients with concurrent CNS tumors and MS and suggests several practical approaches to their clinical management. Our findings suggest that adding a disease-modifying MS therapy to the regimen of patients treated with chemotherapy is necessary only if the patient suffers from a highly active, aggressive course of MS. In view of the lack of prospective trials, individual risk assessments should remain the foundation of the decision on MS treatment in concurrent CNS tumor diseases.
Simple cells in primary visual cortex were famously found to respond to low-level image components such as edges. Sparse coding and independent component analysis (ICA) emerged as the standard computational models for simple cell coding because they linked their receptive fields to the statistics of visual stimuli. However, a salient feature of image statistics, occlusions of image components, is not considered by these models. Here we ask if occlusions have an effect on the predicted shapes of simple cell receptive fields. We use a comparative approach to answer this question and investigate two models for simple cells: a standard linear model and an occlusive model. For both models we simultaneously estimate optimal receptive fields, sparsity and stimulus noise. The two models are identical except for their component superposition assumption. We find the image encoding and receptive fields predicted by the models to differ significantly. While both models predict many Gabor-like fields, the occlusive model predicts a much sparser encoding and high percentages of ‘globular’ receptive fields. This relatively new center-surround type of simple cell response is observed since reverse correlation is used in experimental studies. While high percentages of ‘globular’ fields can be obtained using specific choices of sparsity and overcompleteness in linear sparse coding, no or only low proportions are reported in the vast majority of studies on linear models (including all ICA models). Likewise, for the here investigated linear model and optimal sparsity, only low proportions of ‘globular’ fields are observed. In comparison, the occlusive model robustly infers high proportions and can match the experimentally observed high proportions of ‘globular’ fields well. Our computational study, therefore, suggests that ‘globular’ fields may be evidence for an optimal encoding of visual occlusions in primary visual cortex.
Immune profile and radiological characteristics of progressive multifocal leukoencephalopathy
(2021)
Background and purpose: Progressive multifocal leukoencephalopathy (PML) constitutes a severe disease with increasing incidence, mostly in the context of immunosuppressive therapies. A detailed understanding of immune response in PML appears critical for the treatment strategy. The aim was a comprehensive immunoprofiling and radiological characterization of magnetic resonance imaging (MRI) defined PML variants.
Methods: All biopsy-confirmed PML patients (n = 15) treated in our department between January 2004 and July 2019 were retrospectively analysed. Data from MRI, histology as well as detailed clinical and outcome data were collected. The MRI-defined variants of classical (cPML) and inflammatory (iPML) PML were discriminated based on the intensity of gadolinium enhancement. In these PML variants, intensity and localization (perivascular vs. parenchymal) of inflammation in MRI and histology as well as the cellular composition by immunohistochemistry were assessed. The size of the demyelinating lesions was correlated with immune cell infiltration.
Results: Patients with MRI-defined iPML showed a stronger intensity of inflammation with an increased lymphocyte infiltration on histological level. Also, iPML was characterized by a predominantly perivascular inflammation. However, cPML patients also demonstrated certain inflammatory tissue alterations. Infiltration of CD163-positive microglia and macrophage (M/M) subtypes correlated with PML lesion size.
Conclusions: The non-invasive MRI-based discrimination of PML variants allows for an estimation of inflammatory tissue alterations, although exhibiting limitations in MRI-defined cPML. The association of a distinct phagocytic M/M subtype with the extent of demyelination might reflect disease progression.
The acute superficial siderosis syndrome — clinical entity, imaging findings, and histopathology
(2022)
Superficial siderosis is a consequence of repetitive bleeding into the subarachnoid space, leading to toxic iron and hemosiderin deposits on the surface of the brain and spine. The clinical and radiological phenotypes of superficial siderosis are known to manifest over long time intervals. In contrast, this study defines the “acute superficial siderosis syndrome” and illustrates typical imaging and histopathological findings of this entity. We describe the case of a 61-year-old male patient who was diagnosed with a melanoma metastasis in the right frontal cortex in February 2019. Within a few weeks he developed a progressive syndrome characterized by cerebellar ataxia, gait disturbance, signs of myelopathy, and radiculopathy. MRI revealed ongoing hemorrhage from the metastasis into the lateral ventricle and the subarachnoid space. A semiquantitative assessment of three subsequent MRI within an 8-week period documented the rapid development of superficial siderosis along the surface of the cerebellum, the brain stem, and the lower parts of the supratentorial regions on T2*-weighted sequences. The diagnosis of a superficial siderosis was histopathologically confirmed by identifying iron and hemosiderin deposits on the cortex along with astrogliosis. The recognition of this “acute superficial siderosis syndrome” triggered surgical removal of the hemorrhagic metastasis. Based on a single case presentation, we define the “acute superficial siderosis syndrome” as a clinical entity and describe the radiological and histopathological characteristics of this entity. Early recognition of this syndrome may allow timely elimination of the bleeding source, in order to prevent further clinical deterioration.
Purpose: Seizures pose a significant burden in patients with primary and secondary brain tumors during the end-of-life period. A wide range of 6 to 56% of clinically observed epileptic seizures at the end of life has been reported. We aimed to analyse the incidence of epileptic seizures at the end of life in brain tumor patients more accurately using not only clinical but also electrophysiological findings.
Methods: This retrospective, single center study included brain tumor patients who died during the stay on the ward or within 7 days after discharge between 01/2015 and 08/2020. Clinical observation of seizures derived from the original medical records and EEG findings (within 45 days prior to death) were analyzed to determine the incidence of seizures in that period.
Results: Of the 68 eligible patients, 50 patients (73.5%) suffered from seizures within 45 days prior to death, of which n = 24 had a status epilepticus. The diagnosis of seizures/ status epilepticus was determined either by the presentation of clinical signs in 45 patients and if not, by the detection of a (possible) non-convulsive status epilepticus in the EEG of five patients.
Conclusion: In the presence of neurologically trained staff and with the frequent use of routine EEG, we were able to identify seizures and to distinguish status epilepticus from encephalopathy/ hypoactive delirium. We detected a higher incidence of seizures and status epilepticus at the end of life in neurooncological patients than previously reported.
Background: Hypoxia is a key driver for infiltrative growth in experimental gliomas. It has remained elusive whether tumor hypoxia in glioblastoma patients contributes to distant or diffuse recurrences. We therefore investigated the influence of perioperative cerebral ischemia on patterns of progression in glioblastoma patients.
Methods: We retrospectively screened MRI scans of 245 patients with newly diagnosed glioblastoma undergoing resection for perioperative ischemia near the resection cavity. 46 showed relevant ischemia nearby the resection cavity. A control cohort without perioperative ischemia was generated by a 1:1 matching using an algorithm based on gender, age and adjuvant treatment. Both cohorts were analyzed for patterns of progression by a blinded neuroradiologist.
Results: The percentage of diffuse or distant recurrences at first relapse was significantly higher in the cohort with perioperative ischemia (61.1%) compared to the control cohort (19.4%). The results of the control cohort matched well with historical data. The change in patterns of progression was not associated with a difference in survival.
Conclusions: This study reveals an unrecognized association of perioperative cerebral ischemia with distant or diffuse recurrence in glioblastoma. It is the first clinical study supporting the concept that hypoxia is a key driver of infiltrative tumor growth in glioblastoma patients.